Queen's Gazette | Queen's University

Search form

News Release - ERYTECH collaborates with Queen's University to advance its platform in the field of rare metabolic disorders

Friday, June 30, 2017

LYON, FRANCE - Queen’s University researcher Colin Funk is teaming up with French clinical-stage biopharmaceutical company ERYTECH Pharma to work toward developing innovative therapies for rare forms of cancer and orphan diseases.

Queen’s and ERYTECH have entered into a research collaboration to advance the pre-clinical development of the company’s eryminase program for Arginase 1 Deficiency, a rare and severe metabolic disorder of arginine metabolism.

Arginase 1 Deficency is a rare, inherited disorder of the urea cycle caused by a mutation in the Arginase-1 gene leading to the accumulation of toxic levels of arginine in the blood. Symptoms generally appear in early infancy and include intellectual disability, spastic movements and seizures. It is a seriously debilitating, progressive disease with very limited treatment options.

“Arginase-1 Deficiency is a severe, rare disorder affecting a biochemical pathway that disposes of toxic ammonia,” says Dr. Funk. “Normally our bodies are very efficient at removing any ammonia that accumulates after eating a protein-rich meal. However, in these patients the ammonia is ‘partially detoxified’ leading to a large accumulation of the amino acid arginine in the blood and brain.”

“ERYTECH’s approach with eryminase is directed towards reducing the level of arginine in blood and has thus a significant potential to reduce negative consequences of the disorder. We look forward to working with ERYTECH to advance this preclinical program.”

- 30 -

Queen’s distinguishes itself as one of the leading research-intensive institutions in Canada. The mission is to advance research excellence, leadership and innovation, as well as enhance Queen’s impact at a national and international level. Through undertaking leading-edge research, Queen’s is addressing many of the world’s greatest challenges, and developing innovative ideas and technological advances brought about by discoveries in a variety of disciplines. Queen’s University is a member of the U15 Group of Canadian Research Universities.

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs.


Anne Craig, Media Relations Officer

613-533-2877 or anne.craig@queensu.ca

Related Experts